Cite
Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910-1920doi: 10.1038/s41591-021-01541-0.
Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Davila, R., Dudek, A. Z., Borghaei, H., Lanis, M., Belcaid, Z., Smith, K. N., Balan, A., White, J. R., Cherry, C., Ashok Sivakumar, I. K., Shao, X. M., Chan, H. Y., Singh, D., Thapa, S., Illei, P. B., Pardoll, D. M., Karchin, R., Velculescu, V. E., Brahmer, J. R., & Ramalingam, S. S. (2021). Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine, 27(11), 1910-1920. https://doi.org/10.1038/s41591-021-01541-0
Forde, Patrick M, et al. "Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial." Nature medicine vol. 27,11 (2021): 1910-1920. doi: https://doi.org/10.1038/s41591-021-01541-0
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 Nov;27(11):1910-1920. doi: 10.1038/s41591-021-01541-0. Epub 2021 Nov 08. PMID: 34750557; PMCID: PMC8604731.
Copy
Download .nbib